| Unknown | YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma Advanced Sarcoma, Metastatic Sarcoma, Soft Tissue Sarcoma | Phase 1 / Phase 2 | 2022-11-14 |
| Active Not Recruiting | ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma | Phase 2 | 2020-12-09 |
| Unknown | Study of TJ004309 in Combination With Atezolizumab (Tecentriq®) in Patients With Advanced or Metastatic Cancer Solid Tumor, Metastatic Cancer | Phase 1 | 2019-07-16 |
| Completed | Study of Carotuximab (TRC105) Plus Nivolumab in Patients With Metastatic NSCLC Carcinoma, Non-Small-Cell Lung | Phase 1 | 2017-11-09 |
| Completed | Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cance Metastatic Castrate-resistant Prostate Cancer, Adenocarcinoma, Prostate | Phase 1 / Phase 2 | 2017-05-23 |
| Completed | Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients With Advanced Angiosarcoma Advanced Angiosarcoma | Phase 3 | 2017-02-13 |
| Completed | Trial of TRC105 and Sorafenib in Patients With HCC Hepatocellular Carcinoma | Phase 1 / Phase 2 | 2016-11-01 |
| Terminated | Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN) Gestational Trophoblastic Neoplasia, Choriocarcinoma, Placental Site Trophoblastic Tumor | Phase 2 | 2016-03-01 |
| Completed | Study of TRC105 + Paclitaxel/Carboplatin and Bevacizumab in Patients With NSCLC Non Small Cell Lung Cancer | Phase 1 | 2015-09-01 |
| Completed | TRC105 Combined With Standard-dose Bevacizumab for Two Patients With Metastatic And Refractory Choriocarcinoma Choriocarcinoma | Phase 2 | 2015-01-01 |
| Completed | A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patient Advanced Soft Tissue Sarcoma | Phase 1 / Phase 2 | 2013-12-10 |
| Terminated | Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma Renal Cell Carcinoma | Phase 1 / Phase 2 | 2013-03-08 |
| Completed | A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab in Patients With Glioblastoma Glioblastoma, Glioblastoma Multiforme | Phase 2 | 2012-05-01 |
| Completed | Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Recurrent Ovarian Cancer, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma | Phase 2 | 2011-07-01 |
| Completed | Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast Cancer Metastatic Breast Cancer | Phase 1 / Phase 2 | 2011-06-01 |
| Completed | Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is Ind Adult Solid Tumor | Phase 1 | 2011-04-01 |
| Completed | Study of TRC102 in Combination With Pemetrexed in Cancer Patients Neoplasm | Phase 1 | 2008-06-01 |
| Completed | Open Label Phase 1 Dose Finding Study of TRC105 in Patients With Solid Cancer Cancer, Neoplasm Metastasis | Phase 1 | 2007-12-01 |
| Completed | Phase 1, Open-label, Dose Escalation Study of TRC093, in Patients With Locally Advanced or Metastatic Solid Tu Cancer, Neoplasm Metastasis | Phase 1 | 2007-06-01 |
| No Longer Available | Open Label Continuation Study of TRC105 for Patients Who Have Completed a Prior TRC105 Trial Solid Tumors | — | — |